New bladder cancer drug offers hope for avoiding bladder removal

NCT ID NCT07468851

Not yet recruiting Disease control Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Mar 17, 2026 · Last updated May 19, 2026 · Updated 6 times

Summary

This study tests a new drug called HS-10566 in people with high-risk bladder cancer that hasn't spread into the muscle wall. It is for those who cannot have or choose not to have their bladder removed. The study has two parts: first finding the best dose, then checking how well it works at controlling the cancer. About 180 adults will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Nanjing Drum Tower Hospital

Nanjing, 210008, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Peking University First Hospital

Beijing, 100034, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER